Syndax Pharmaceuticals Inc. has announced the granting of inducement awards as part of its 2023 Inducement Plan. Effective July 1, 2025, the company has provided stock options to purchase up to 228,400 shares of common stock to 14 new employees. These options will vest over a period of four years, with an initial 25% of the shares vesting on the first anniversary of the vesting commencement date. Thereafter, 1/48th of the shares will vest monthly over the following 36 months, contingent on the employees' continued service with the company.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。